Multitargeting Histamine H3 Receptor Ligands among Acetyl- and Propionyl-Phenoxyalkyl Derivatives
Authors:
- Dorota ŁażewskaDŁDorota Łażewska
- Maria KaletaMKMaria Kaleta
- Paula ZarębaPZPaula Zaręba
- Justyna GodyńJGJustyna Godyń
- Mariam DubielMDMariam Dubiel
- Ewelina Honkisz-OrzechowskaEHEwelina Honkisz-Orzechowska
- Agata Doroz-PłonkaADAgata Doroz-Płonka
- Anna WięckowskaAWAnna Więckowska
- Holger StarkHSHolger Stark
- Katarzyna Kieć-KononowiczKKKatarzyna Kieć-Kononowicz
Open Access
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder, for which there is no effective cure. Current drugs only slow down the course of the disease, and, therefore, there is an urgent need to find effective therapies that not only treat, but also prevent it. Acetylcholinesterase inhibitors (AChEIs), among others, have been used for years to treat AD. Histamine H3 receptors (H3Rs) antagonists/inverse agonists are indicated for CNS diseases. Combining AChEIs with H3R antagonism in one structure could bring a beneficial therapeutic effect. The aim of this study was to find new multitargetting ligands. Thus, continuing our previous research, acetyl- and propionyl-phenoxy-pentyl(-hexyl) derivatives were designed. These compounds were tested for their affinity to human H3Rs, as well as their ability to inhibit cholinesterases (acetyl- and butyrylcholinesterases) and, additionally, human monoamine oxidase B (MAO B). Furthermore, for the selected active compounds, their toxicity towards HepG2 or SH-SY5Y cells was evaluated. The results showed that compounds 16 (1-(4-((5-(azepan-1-yl)pentyl)oxy)phenyl)propan-1-one) and 17 (1-(4-((6-(azepan-1-yl)hexyl)oxy)phenyl)propan-1-one) are the most promising, with a high affinity for human H3Rs (Ki: 30 nM and 42 nM, respectively), a good ability to inhibit cholinesterases (16: AChE IC50 = 3.60 µM, BuChE IC50 = 0.55 µM; 17: AChE IC50 = 1.06 µM, BuChE IC50 = 2.86 µM), and lack of cell toxicity up to 50 µM.Keywords
Funding Information
- agiellonian University Medical College in Kraków (N42/DBS/000300, GRK2158)
- Deutsche Forschungsgemeinschaft (N42/DBS/000300, GRK2158)
This publication has 35 references indexed in Scilit:
- Biphenyloxy-alkyl-piperidine and azepane derivatives as histamine H3 receptor ligandsBioorganic & Medicinal Chemistry, 2017
- Prediction of liver toxicity and mode of action using metabolomics in vitro in HepG2 cellsArchives of Toxicology, 2017
- Histamine H3R Antagonists: From Scaffold Hopping to Clinical Candidates2016
- The Histamine H3 Receptor: Structure, Pharmacology, and FunctionMolecular Pharmacology, 2016
- Histamine H3 Receptor Antagonists for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled TrialsJournal of Alzheimer’s Disease, 2015
- International Union of Basic and Clinical Pharmacology. XCVIII. Histamine ReceptorsPharmacological Reviews, 2015
- Revisiting the cholinergic hypothesis in the development of Alzheimer's diseaseNeuroscience & Biobehavioral Reviews, 2011
- Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligandsEuropean Journal of Pharmacology, 2011
- Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptorNature, 1983
- A new and rapid colorimetric determination of acetylcholinesterase activityBiochemical Pharmacology, 1961